All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Miltenyi Biomedicine, Nurix Therapeutics, Roche, Sobi, and Thermo Fisher Scientific and supported through educational grants from Bristol Myers Squibb, Eli Lilly, and Pfizer. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
Results from the phase II, open-label, single-arm, multicenter JACKPOT26 trial (NCT06511869), evaluating golidocitinib maintenance in adults with peripheral T‑cell lymphoma (PTCL) who achieved complete response (CR; Cohort 1; n = 30) or partial response (PR; Cohort 2; n = 18) after first-line systemic therapy, were published in Blood Cancer Journal by Wei et al. Enrolled patients were transplant-ineligible or did not have a transplant plan. The primary endpoints were adverse events (AEs) and serious adverse events (SAEs).
Key data: In Cohort 1, median disease-free survival (DFS) was 25.7 months, with 12- and 24-month DFS rates of 82.1% and 74.2%, respectively. In Cohort 2, median progression-free survival (PFS) was 17.4 months, with 12- and 24-month PFS rates of 68.8% and 48.6%, respectively. The CR rate among patients with an initial PR was 50%. With a median follow-up of 30.5 and 28.6 months, the median overall survival (OS) was not reached in either cohort. In the overall cohort, Grade ≥3 treatment-related adverse events (TRAEs) occurred in 72.9% of patients and treatment-related SAEs (TRSAEs) in 29.2%; the most common Grade ≥3 TRAEs were decreased neutrophil count (47.9%), decreased white blood cell count (31.3%), decreased lymphocyte count (14.6%), pneumonia (14.6%), and leukopenia (12.5%). TRAEs led to treatment interruption in 60.4% of patients, dose reduction in 16.7%, and discontinuation in 10.0%, with no fatal TRAEs reported.
Key learning: Golidocitinib maintenance therapy demonstrated a manageable safety profile with encouraging efficacy in patients with PTCL following first-line treatment, supporting its continued evaluation as a maintenance option for transplant-ineligible patients with PTCL.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
In your experience, what is the average vein-to-vein time when treating patients with DLBCL with a reimbursed CAR T-cell therapy (from apheresis to infusion)?